›› KLIFOVET › EXPERTISE › PUBLICATIONS

Multicenter Randomized, and Blinded European Field Study Evaluating the Efficacy and Safety of Felpreva®, a Novel Spot-On Formulation Containing Emodepside, Praziquantel and Tigolaner in Treating Cats Naturally Infested with Fleas And/Or Ticks

The present field study has evaluated the safety and three month preventive efficacy of a novel spot-on endectocide containing emodepside 2.04 w/v, praziquantel 8.14 w/v and tigolaner 9.79 w/v (Felpreva®, Vetoquinol) when administered at the intended commercial dose of 0.15 mL/kg body weight to privately owned cats infested by fleas (Ctenocephalides felis) and/or ticks (Ixodes ricinus, Ixodes hexagonus, Rhipicephalus spp.). The efficacy of Felpreva® to reduce the clinical signs associated with flea allergy dermatitis was also evaluated. A total of 326 cats, i.e. 120 and 206 infested by ticks and fleas respectively, from 16 different sites located in Hungary and Portugal were included on Study Day 0 and allocated in two Groups in a ratio of 2:1 (T1:T2). Cats of T1 were treated with Felpreva®, while cats of T2 were dosed with a commercial Control Product (Bravecto®, MSD Animal Health) licensed for the same indications. Of the 120 cats infested by ticks, 79 and 41 were treated with Felpreva® and Bravecto® respectively, while of the 206 flea-infested cats, 139 were treated with the Felpreva® and 67 with the Bravecto®. Cats were physically examined on Study Days (SD) 7, 28, 56, 75 and 90; when present fleas and ticks were counted and collected. Efficacy evaluation was based on the mean percent reduction of live parasite counts for each of five visits versus the pre-treatment count. Percent reduction of live flea and tick counts over all post-baseline periods was 99.74% (T1) - 98.56% (T2) and 97.50% (T1) - 98.65% (T2), respectively. Non-inferiority for the Felpreva® compared with the Bravecto® was statistically demonstrated for both fleas and ticks. Three adverse events were observed and considered unlikely related to the treatment. These results show that the new topical combination product Felpreva® is safe and highly efficacious in treating flea and tick infections in cats for at least three months (90 days) with a single administration. In 16 cats that were identified with flea allergy dermatitis, the clinical signs of flea allergy dermatitis improved following treatment in both groups

DATE » 31.01.2022

AUTHORS » Dejan Cvejića , Klaus Hellmanna , Gabriele Petryb , Hannah Ringeisenb , Hannah Hamburgb , Róbert Farkasc , Katrin Blazejakd , Norbert Mencked a Klifovet GmbH, Geyerspergerstr. 27, 80689 München, Germany b Bayer Animal Health GmbH an Elanco Animal Health Company, Alfred Nobel Str. 50, 40789 Monheim, Germany c Faculty of Veterinary Medicine, Szent István University, Department of Parasitology and Zoology, István u. 2, Budapest 1078, Hungary d Vetoquinol, Department of Medical Marketing Parasitology, 37 rue de la Victoire, 75009 Paris, France

PUBLISHED » https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4064464